Beam Therapeutics Inc. (BEAM) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Beam Therapeutics Inc. is a clinical-stage biotechnology company developing precision genetic medicines using its proprietary base editing platform. The company focuses on treating genetic diseases, including sickle cell disease (risto-cel), alpha-1 antitrypsin deficiency (BEAM-302), phenylketonuria (BEAM-304), and glycogen storage disease type 1a (BEAM-301). As of July 28, 2026, there were 103,287,665 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6 Months 2026 | 6 Months 2025 |
|---|---|---|---|---|
| Revenue | $490 | $8,466 | $32,228 | $15,936 |
| Net Loss | $(122,678) | $(102,138) | $(216,996) | $(210,468) |
| Loss Per Share (Basic/Diluted) | $(1.18) | $(1.00) | $(2.09) | $(2.21) |
| Operating Expenses | $127,043 | $128,617 | $265,996 | $255,373 |
| Cash & Cash Equivalents | $219,825 | $282,132 | $219,825 | $282,132 |
| Marketable Securities | $933,102 | $950,266 | $933,102 | $950,266 |
| Total Liquidity | $1,152,927 | $1,232,398 | $1,152,927 | $1,232,398 |
| Long-Term Debt | $100,258 | $0 | $100,258 | $0 |
Note: Revenue is derived solely from license and collaboration agreements; no product sales revenue has been generated.
Material Changes vs. Prior Period
- Revenue Volatility: Q2 2026 revenue dropped significantly to $0.5 million from $8.5 million in Q2 2025 due to a decrease in research activity levels under collaboration agreements. However, for the six-month period, revenue increased to $32.2 million (from $15.9 million) driven by a $25.0 million milestone recognition from the Eli Lilly agreement.
- Debt Financing: In February 2026, the company entered a credit facility with Sixth Street Lending Partners, drawing an initial $100 million. This resulted in a new long-term debt liability of approximately $100.3 million, compared to zero debt in the prior year.
- Operating Expenses: Total operating expenses remained relatively flat quarter-over-quarter ($127.0M vs $128.6M). Research and Development (R&D) expenses decreased slightly due to lower external service costs, partially offset by increased employee-related costs. General and Administrative (G&A) expenses increased by $5.1 million, primarily due to higher employee costs and legal fees.
- Other Income/Expense: The company recorded a $4.2 million expense related to the change in fair value of derivative liabilities (success payments to Harvard and Broad Institute) in Q2 2026, compared to $1.3 million income in Q2 2025, driven by stock price fluctuations.
Guidance, Outlook, and Risks
- Clinical Progress:
- risto-cel (Sickle Cell): Dosing in the BEACON Phase 1/2 trial is complete. Updated data showed durable high editing efficiency and resolution of anemia. The company expects to submit a Biologics License Application (BLA) as early as year-end 2026.
- BEAM-302 (AATD): Phase 1/2 data showed rapid increases in functional AAT and durable reduction of mutant Z-AAT. The company intends to pursue an accelerated approval pathway and dosed the first patient in the pivotal cohort in July 2026.
- BEAM-304 (PKU): FDA cleared the IND application in June 2026; clinical start-up activities have begun.
- Liquidity Outlook: Management expects cash, cash equivalents, and marketable securities of $1.2 billion to fund operations for at least the next 12 months. The company anticipates needing additional financing in the future to support growth and operations.
- Risks and Contingencies:
- Intellectual Property: Significant risks exist regarding patent validity and priority disputes, particularly involving CRISPR/Cas9 technologies with the University of California and Toolgen. Recent PTAB decisions favor the Boston Licensing Parties, but appeals are possible.
- Success Payments: The company has contingent liabilities for success payments to Harvard and Broad Institute, which fluctuate with the company's stock price.
- Debt Covenants: The new credit facility includes financial covenants requiring the maintenance of specific liquidity levels ($40M - $125M depending on market cap and drawdowns).
Investor Verification Checklist
- BLA Timeline: Verify the feasibility of the year-end 2026 BLA submission for risto-cel given the complexity of the manufacturing and regulatory process.
- Debt Covenants: Monitor the company's market capitalization and liquidity levels to ensure compliance with the Sixth Street credit facility covenants.
- IP Litigation Status: Track the status of the PTAB interference proceedings (No. 106,115 and No. 106,126) regarding CRISPR priority, as adverse outcomes could block commercialization.
- Success Payment Liability: Assess the potential cash impact of success payments to Harvard and Broad Institute if the company's stock price appreciates significantly.
- Cash Burn Rate: Confirm the sustainability of the $1.2 billion liquidity position against the projected increase in operating expenses for clinical trials and manufacturing.